Brian Lehmann

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)

Clinical trial shows efficacy for atezolizumab combined with carboplatin

‘Multi-omics’ reveals treatment option for breast cancer subtype

VICC investigators land support from Komen Foundation

Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

Komen grants bolster breast cancer research

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research.